A Phase 1b/2 Study of ERAS-601 in People With Chordoma

Full Title

A Phase 1b/2 Study of ERAS-601 SHP2 Inhibitor as a Monotherapy in Patients with Advanced and Progressing Chordoma

Purpose

Chordoma is a type of bone cancer that develops in the spine or the base of the skull. Researchers are doing this study to learn if ERAS-601 is safe and works well in people with chordoma. The people in this study have chordoma that is inoperable (cannot be taken out with surgery) or has spread.

ERAS-601 targets a protein called SHP2, which is found on chordoma cancer cells and plays a role in their growth. By blocking this protein, ERAS-601 may help slow or stop the growth of your cancer. It is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have chordoma that is inoperable or has spread.
• Have chordoma with dimensions that have increased by 20 percent in the last 9 months.
• Have recovered from the serious side effects of previous chordoma therapies.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Mrinal Gounder’s office at 646-888-4167.